Article PDF
Avoid common mistakes on your manuscript.
References
Palker TJ, Clark ME, Longlois AJ, et al. (1988) Type-specific neutralization of HIV-1 with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 85: 1932
Palker TJ, Matthews TJ, Langlois A, et al. (1989) Polyvalent HIV-1 synthetic immunogen comprised of envelope gp 120 T helper cells sites and B cell neutralization epitops. J Immunol 142: 3612
Haynes BF, Tores JV, Langlois AJ, et al. (1993) Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp 120 envelope peptides. J Immunol 151: 1646
Hoth DF, Bolognese DP, Corey L, Vermund SH (1994) HIV vaccine development. A progress report. Ann Int Med 8: 603
Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 138
Pialoux G, Exceller JL, Riviere Y et al. (1995) A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing gp 160 (MN) followed by recombinant gp 160 (MN/LAI). AIDS Rs and Human Retroviruses 11: 373
Layton GT, Harris SJ, Gearing AJH, Adams S (1993) Induction of HIV-specific CTL in vivo with hybrid HIV-1 V3: Ty-virus-like particles. J Immunol 151: 1079
Nardelli U, Tan PM (1993) Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide. Immunology 79: 355
Gorse CJ, Keefer M, Weinhold K, et al. (1994) NIAID AIDS Vaccine Clinical Trials Network. Phase I study of HIV-1MN V3 octameric peptide vaccine. X International Conference on AIDS. Yokohama, August 1994 (abstract PAO375)
Rubinstein A, Goldstein H, Pettoello-Mantovani M, Mizrachi Y, Bloom BR, Furer E, Althaus B, Que JU, Hasler T, Cryz SJ Jr (1995) Safety immunogenicity of a V3 loop PPD conjugateprimary neutralizing domain (PND) synthetic peptide-toxin A conjugate vaccine. Vaccine 13: 67
Safrit JT, Lee AY, Andrews CA, Koup RA (1994) A region of the third variable loop of HIV-1 gp 120 is recognized by HLA-B7 restricted CTL from two acute seroconversion patients. J Immunol 153: 3822
Berzofsky JA, Ahlers JO, Shira M, et al. (1993) Construction of candidate synthetic peptide vaccines for HIV-1. VI Conference of Advances in AIDS Vaccine Development
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rubinstein, A., Cryz, S. Preventive and therapeutic AIDS peptide vaccines. Eur J Pediatr 154 (Suppl 4), S28–S29 (1995). https://doi.org/10.1007/BF02191502
Issue Date:
DOI: https://doi.org/10.1007/BF02191502